Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor

International Journal of Pharmaceutics

Volumn 454, Issue 1, 2013, Pages 241-248

  Cui, Yong ^a   Chiang, Po Chang ^a   Choo, Edna F ^a   Boggs, Jason ^a   Rudolph, Joachim ^a   Grina, Jonas ^b   Wenglowsky, Steve ^b   Rana, Yingqing ^a  

^a GENENTECH INC   (United States)

^b ARRAY BIOPHARMA INC   (United States)

Author keywords

B Raf; Bioavailability; Dissolution; Prediction; SDD; Solubility

Indexed keywords

2,6 DIFLUORO N [3 METHOXY 1H PYRAZOLO(3,4B)PYRIDIN 5 YL] 3 (PROPYLSULFONAMIDO)BENZAMIDE; B RAF KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEASIBILITY STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; X RAY DIFFRACTION;

EID: 84884146922     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.064     Document Type: Article

References (28)

1. Al-Obaidi, H., Brocchini, S., Buckton, G., 2009. Anomalous properties of spray dried solid dispersions. J. Pharm. Sci. 98, 4724-4737.
2. Alonzo, D.E., Zhang, G.Z., Zhu, D., Gao, Y., Taylor, L.S., 2009. Understanding the behavior of amorphous pharmaceutical system during dissolution. Pharm. Res. 27, 608-618.
3. Augustijns, P., Brew, M.E., 2012. Supersaturating drug delivery systems: fast is not necessarily good enough. J. Pharm. Sci. 101, 7-9.
4. Brouwers, J., Brwerster, M.E., Augustijins, P., 2009. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability. J. Pharm. Sci. 98, 2549-2572.
5. Chiang, P., Hu, Y., 2009. Simultaneous determination of log D, log P, and pKa of drugs by using a reverse phase HPLC coupled with a 96-well plate auto injector. Comb. Chem. High Throughput Screen. 12, 250-257.
6. Chiang, P., Ran, Y., Chou, K.J., Cui, Yong, Sambrone, A., Chan, C., Hart, R., 2012. Evaluation of drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery. AAPS PharmSciTech 13, 713-722.
7. Choo, E.F., Alicke, B., Boggs, J., Dinkel, V., Gould, S., Grina, J., West, H., Menghrajani, K., Ran, Y., Rudolph, J., Wenglowsky, S., 2011. Preclinical assessment of Novel B-Raf Inhibitors: integration pharmacokinetic-pharmacodynamic modeling in the drug discovery process. Xenobiotica 41, 1076-1087.
8. Curatolo, W., Nightingale, J.A., Herbig, S.M., 2009. Utility of hydroxypropylmethyl-cellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu. Pharm. Res. 26, 1419-1431.
9. Friesen, D.T., Shanker, R., Crew, M., Smithey, D.T., Curatolo, W.J., Nightingale, J.A.S., 2008. Hydroxyproply methylcellulose acetate succinate-based spray-dried dispersion: an overview. Mol. Pharm. 5, 1003-1019.
10. Hancock, B., Shamblin, S., Zografi, G., 1995. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res. 12, 799-806.
11. Hauss, D.J., 2007. Oral lipid-based formulations. Adv. Drug Deliv. Rev. 59, 667-676. (Pubitemid 47285409)
12. Konno, H., Taylor, L.S., 2006. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J. Pharm. Sci. 95, 2692-2705. (Pubitemid 46093176)
13. Leuner, C., Dressman, J., 2000. Improving drug solubility for oral delivery using solid dispersion. Eur. J. Pharm. Biopharm. 50, 47-60. (Pubitemid 30326688)
14. Li, P., Zhao, L., 2007. Developing early formulations: practice and perspective. Int. J. Pharm. 341, 1-19. (Pubitemid 47088122)
15. Loftsson, T., Brewster, M.E., 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85, 1017-1025.
16. Pouton, C.W., 2000. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 11, S93-S98.
17. Pouton, C.W., 2006. Formulation of poorly water-soluble drugs for oral administration: physico-chemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 29, 278-287. (Pubitemid 44740131)
18. Puri, V., Dantuluri, A.K., Bansal, A.K., 2010. Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion. J. Pharm. Sci. 100, 2460-2468.
19. Rajewski, R.A., Stella, V.J., 1996. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85, 1142-1169.
20. Ran, Y., Jain, A., Yalkowsky, S.H., 2005. Solubilization and pre-formulation studies on PG-300995 (an anti-HIV drug). J. Pharm. Sci. 94, 297-303. (Pubitemid 40293326)
21. Ran, Y., 2012. Formulation Development for G-F in Preclinical Studies (unpublished data).
22. Serajuddin, A.T., 1999. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthrough. J. Pharm. Sci. 88, 1058-1066.
23. Shanbhag, A., Rabel, S., Nauka, E., Casadevall, G., Shivanand, P., Eichenaum, G., Mansky, P., 2008. Method for screening of solid dispersion formulations of low-solubility compounds-miniaturization and automation of solvent casting and dissolution testing. Int. J. Pharm. 351, 209-218. (Pubitemid 351186860)
24. Stillinger, F., 1998. Enumeration of isobaric inherent structures for the fragile glass former o-terphenyl. J. Phys. Chem. B 102, 2807-2810. (Pubitemid 128606327)
25. Strickley, R.G., 2004. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21, 201-230. (Pubitemid 38221966)
26. Taylor, L.S., Zografi, G., 1997. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersion. Pharm. Res. 14, 1691-1698. (Pubitemid 28062912)
27. Wenglowsky, S., Ren, L., Ahrendt, K.A., Laird, E.R., Aliagas, I., Alicke, B., Buckmelter, A.J., Choo, E.F., Dinkel, V., Feng, B., Gloor, S.L., Gould, S.E., Gross, S., Gunzner-Toste, J., Hansen, J.D., Hatzivassiliou, G., Liu, B., Malesky, K., Mathieu, S., Newhouse, B., Raddatz, N.J., Ran, Y., Rana, S., Randolph, N., Risom, T., Rudolph, J., Savage, S., Selby, L.T., Shrag, M., Song, K., Sturgis, H.L., Voegtli, W.C., Wen, Z., Willis, B.S., Woessner, R.D., Wu, W., Young, W.B., Grina, J., 2011. Pyrazolopyridine inhibitors of B-RafV600E. Part 1: the development of selective, orally bioavailable, and efficacious inhibitors. ACS Med. Chem. Lett. 2, 342-347.
28. Yalkowsky, S.H., 1999. Solubility and solubilization in aqueous media. ACS Press, Washington, DC.